Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Upgraded by Oppenheimer

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by Oppenheimer from a “market perform” rating to an “outperform” rating in a research report issued on Monday, Marketbeat.com reports. The firm currently has a $490.00 target price on the biopharmaceutical company’s stock. Oppenheimer’s price objective suggests a potential upside of 16.97% from the stock’s current price.

A number of other research analysts have also recently commented on ALNY. Wells Fargo & Company raised their price target on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an “equal weight” rating in a research note on Friday, August 1st. Truist Financial assumed coverage on Alnylam Pharmaceuticals in a research report on Monday, July 21st. They set a “buy” rating and a $385.00 target price for the company. Bank of America upped their price target on Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the company a “buy” rating in a research report on Friday, July 11th. Scotiabank increased their price objective on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a “sector outperform” rating in a research note on Friday, August 1st. Finally, Wolfe Research upgraded shares of Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research note on Monday. Four investment analysts have rated the stock with a hold rating and twenty-four have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $396.04.

Alnylam Pharmaceuticals Stock Down 0.2%

ALNY stock opened at $418.91 on Monday. Alnylam Pharmaceuticals has a twelve month low of $205.87 and a twelve month high of $426.76. The company has a quick ratio of 2.98, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The company has a market cap of $54.91 billion, a PE ratio of -169.60 and a beta of 0.25. The business’s 50-day simple moving average is $323.41 and its 200 day simple moving average is $281.19.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. The business had revenue of $773,689 billion during the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%. Alnylam Pharmaceuticals’s revenue was up 17.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.13) earnings per share. On average, research analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the firm’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the transaction, the chief executive officer owned 48,948 shares in the company, valued at $14,978,088. This trade represents a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ALNY. SVB Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $27,000. Whipplewood Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 71 shares during the last quarter. Bessemer Group Inc. grew its holdings in Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 69 shares during the period. Park Square Financial Group LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $28,000. Finally, Ameritas Advisory Services LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $42,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.